Semaglutide: The Complete Guide to Sustainable Weight Loss

Semaglutide is a GLP-1 receptor agonist. It mimics glucagon-like peptide-1, a hormone your gut releases after a meal. GLP-1 tells the pancreas to release insulin, slows gastric emptying so food stays in your stomach longer, and signals the brain that you are satisfied.

In practical terms, semaglutide quiets the constant food noise most patients describe. Cravings soften. Portions shrink naturally. Blood sugar stabilizes, which reduces the energy crashes that drive snacking. For patients who have spent years fighting appetite with willpower alone, the shift can feel surreal in the first few weeks.

Because it is delivered as a once-weekly subcutaneous injection, semaglutide keeps GLP-1 signaling steady rather than spiking and crashing the way natural GLP-1 does after a meal.

Semaglutide is FDA-approved for chronic weight management in adults with a BMI of 30 or higher, or 27 or higher with a weight-related condition such as prediabetes, high blood pressure, or sleep apnea. In real-world clinics, it is also used off-label for metabolic dysfunction, PCOS-related weight resistance, and post-menopausal weight gain.

It is not for everyone. Patients with a personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, or active pancreatitis should not use GLP-1s. Pregnant or breastfeeding patients are excluded. Every Summit patient is medically screened before a prescription is ever written.

Month one is titration. Doses start low (typically 0.25 mg weekly) to let your GI system adapt. Most patients feel appetite suppression within the first two weeks, and some early nausea or fullness that fades as the body adjusts.

Months two and three are where visible weight loss typically begins — usually 1 to 2 pounds per week when paired with adequate protein and resistance training. Doses step up every four weeks until the maintenance range (1.7 mg to 2.4 mg weekly) is reached.

By month six, most patients have lost 10% to 15% of their starting body weight, along with meaningful drops in waist circumference, fasting glucose, blood pressure, and inflammatory markers. This is the point where the program shifts from loss to preservation.

Rapid weight loss on any GLP-1 comes with a real risk: losing lean muscle along with fat. Studies estimate that 25% to 40% of weight lost on semaglutide can come from lean tissue if patients do not train and eat properly.

This is why Summit programs are built around a minimum protein floor (0.8 to 1.0 g per pound of goal bodyweight), progressive resistance training two to four days per week, and regular body composition tracking — not just scale weight. Preserving muscle protects your metabolism, your strength, and your ability to keep weight off after the medication is tapered.

The most common side effects are gastrointestinal: nausea, constipation, reflux, and occasional diarrhea. Most are dose-dependent and resolve within days. Slower titration, smaller meals, and adequate hydration handle the vast majority of cases.

Rare but serious risks include pancreatitis, gallbladder disease, and severe dehydration. Summit patients have direct clinician access between visits, so any concerning symptom is addressed the same day rather than left to escalate.

The single biggest predictor of long-term success on semaglutide is not the dose. It is what happens around the medication: how you eat, how you train, and whether you have a plan for tapering off.

Summit patients graduate into a maintenance phase where doses are slowly reduced while nutrition and training habits are reinforced. Body composition, labs, and metabolic markers are re-checked every three to six months so we can catch regain early — not a year later when the damage is done.